胃泌素释放肽前体在小细胞肺癌中的诊断与疗效监测分析  

Monitoring Analysis and Diagnosis of Small Cell Lung Cancer Efficacy of Gastrin Releasing Peptide Precursor

作　　者：林永志[1] 颜水堤[1] 

机构地区：[1]厦门大学附属中山医院检验科,福建厦门361004

出　　处：《中外医疗》2016年第22期89-91,共3页China & Foreign Medical Treatment

摘　　要：目的研究对小细胞肺癌的患者使用胃泌素释放肽前体进行诊断和临床治疗效果监测的意义。方法该研究主要采取回顾性分析方法,对2015年2月—2016年2月该院住院的45例小细胞肺癌(SCLC)患者和45例非小细胞肺癌(NSCLC)使用电化学发光免疫分析法对患者的血清进行分析,分析患者在接受治疗前后体内的血清数值变化。结果胃泌素释放肽前体(Pro GRP)在SCLC中高于NSCLC,组件比较差异有统计学意义,且在接受治疗后患者的治疗效果越好,其血清内的Pro GRP数值下降的越多。Pro GRP、NSE、CEA、CYFRA21-1的敏感性分别为87.63%、66.36%、21.95%、58.91%,特异性分别为95.74%、84.62%、72.36%、89.68%。结论Pro GRP可作为SCLC患者首选的肿瘤血清标记物,并且其数值的变化可用于观察患者的病情是否得到控制。Objective To study the patients with small cell lung cancer using gastrin-releasing peptide precursor significance of diagnosis and clinical therapeutic effect monitoring. Methods this article mainly take retrospective analysis method, in February 2015- February 2016 hospitalized in our hospital of 45 patients with small cell lung cancer（SCLC）and 45 cases of non-small cell lung cancer（NSCLC） using electrochemical luminescence immunity analysis method to analyze the patient＇s serum, analysis of patients undergoing treatment before and after the changes of serum values in the body.Results The gastrin-releasing peptide precursor（ProGRP） higher than that of NSCLC in SCLC, component is statistically significant, and in the treatment of patients with after treatment effect, the better, the more ProGRP numerical falling within its serum. ProGRP, NSE and CEA, the sensitivity of CYFRA21-1 were 87.63%, 66.36%, 21.95%, 58.91%, specificity of95.74%, 84.62%, 72.36% and 89.68% respectively. Conclusion ProGRP can be as the premier serum tumor markers in patients with SCLC, and its numerical changes can be used to observe whether the patient is under control.

关 键 词：胃泌素释放肽前体 小细胞肺癌 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]